

Hepatitis C Treatment Checklists

Prior to Treatment

Labs:

- Immediately prior: Pregnancy test (if applicable)
 Uric Acid (only with ribavirin)
- Within 1 month: CBC with differential
 CMP¹
 PT/INR
 HCV RNA
- Within 3 months: Genotype confirmation
 HBV DNA (if HBV cAb or sAg +)
- Within 6 months: AFP
- Within 1 year: HIV screening
 FibroSure [LabCorp], FibroTest [Quest], FibroSpect [Prometheus], or FibroScan (If any result suggests cirrhosis, calculate Child-Pugh² score)
- Once: Hepatitis B core antibody IgG (HBcAb)
 NS5A RAS (Genotype 3 if failed prior treatment or cirrhotic & treating with Eplclusa)

Miscellaneous:

- Hepatitis A vaccine status (If unknown: draw HAV antibody total IgG)
 Hepatitis B vaccine status (If unknown: draw HBsAg & HBsAb)
 Review drug-drug interactions
 PHQ-9 baseline
 AUDIT-C
 Counsel about pregnancy prevention
 Review & sign Treatment Readiness Attestation
 Review Information Packet at Treatment Start

Monitoring During Treatment

Week 2 (only with ribavirin)

- CBC
 CMP¹

Week 4

- HCV RNA
 CBC
 CMP¹
 Pregnancy test
 HBV DNA³

Weeks 8, 12, 16, 20, & 24

- CBC
 CMP¹
 Pregnancy test
 HBV DNA³
 HCV RNA (only at end of treatment)

Monthly follow-up in clinic or by phone:

- Managing side effects
 Medication adherence discussion
 Alcohol intake
 Birth control reminder
 Refill reminder

1- Sofosbuvir-based regimen - If GFR <30, no safe recommendation.

With ribavirin - If GFR <50, decrease dose (refer to package insert).

2- Child-Pugh Calculator: <https://www.hepatitisc.uw.edu/page/clinical-calculators/ctp>

Child-Pugh B or C- Do not treat with Mavyret™, Zepatier™, or Vosevi®

3- HBV DNA: If cAb+ & HBV DNA (+) pre-treatment **OR** if Hep B carrier **OR** seroconverted carrier, check HBV DNA monthly during treatment & 12 weeks after treatment. If HBV DNA (-) pre-treatment & not a carrier, check again only at end of treatment.

Hepatitis C Treatment Checklists

Monitoring After Treatment:

12 weeks after last dose:

- CBC
- LFTs
- HCV RNA (to test for cure)
- AFP (if more than 6 months since last result)
- HBV DNA³

6 months post-treatment:

- If Advanced Fibrosis or Cirrhosis prior to treatment continue AFP & RUQ q 6 months to screen for hepatocellular carcinoma (HCC)

1 year post-treatment for 5 years:

- Zero to minimal scarring (F0-F2): yearly CBC & LFTs
- Advanced Fibrosis (F3): RUQ US & AFP q 6 months; yearly CBC, LFTs, & AFP
 - Liver Field Clinic appointment every 2-3 years
- Cirrhosis (F4): RUQ US & AFP q 6 months; yearly CBC, CMP, AFP, PT/INR
 - Yearly Liver Field Clinic appointment

1- Sofosbuvir-based regimen - If GFR <30, no safe recommendation.

With ribavirin - If GFR <50, decrease dose (refer to package insert).

2- Child-Pugh Calculator: <https://www.hepatitisc.uw.edu/page/clinical-calculators/ctp>

Child-Pugh B or C- Do not treat with Mavyret™, Zepatier™, or Vosevi®

3- HBV DNA: If cAb+ & HBV DNA (+) pre-treatment **OR** if Hep B carrier **OR** seroconverted carrier, check HBV DNA monthly during treatment & 12 weeks after treatment. If HBV DNA (-) pre-treatment & not a carrier, check again only at end of treatment.